feu vert de la Haute autorité de santé à three vaccines adapted to Omicron for this autumn

This new booster dose will be given during a new vaccination campaign, coupled with the flu shot.

The Haute autorité de santé (HAS) has demonstrated three anti-Covid-19 vaccines adapted to Omicron for a new vaccination campaign planned for automne et couplée à celle contre la grippe, announced on Tuesday, September 20 in a communiqué.

This new dose of rappel will be recommended to persons at risk of severe forms, to their entourage and to caregivers. HAS recommends «indifferently l’un des trois vaccines bivalents» – two developed by Pfizer/BioNTech, the third by Moderna – recently validated by the European Medicines Agency.

“Vaccins adaptés aux souches circulantes”

«Based on available data and in an epidemic context marked by the majority circulation of the BA.5 sub-variant”, HAS recommends to the employer «preferable» l’un de ces vaccins, tous à RNA messager, pour une new dose of rappel automnale. This recommendation will conclude with regard to the initiation of the anti-Covid vaccine administered to the individual.

«À l’image des vaccins contre la grippe saisonnière, updated every year to take into account les viruses, which are more susceptible to circuler pendant l’hiver, les vaccins à ARN bivalents are not pas des nouveaux vaccins mais des vaccins adaptés aux circulating souches», emphasizes at HAS dans son communiqué.

This is the Moderna and Pfizer/BioNTech vaccines targeting the original strains of the virus and the BA.1 variant of Omicron, and the Pfizer/BioNTech vaccines targeting the original strains and BA variants .4 et BA.5 d’Omicron.

Case d’infections en hausse

The HAS kept parallel with the recommendation of coupling the campaign of the vaccination recall contre la Covid-19 à celle de vaccinare contre la grippe, which started on October 18. A concomitant injection ou le même jour des deux vaccines is possible, rappelle-t-elle.

«Dans l’immédiat et parce que le nombre de cas d’infections is spread over several days», cette autorité sanitaire recomand de no longer différer at the second dose of rappel chez les plus de 60 ans et les moins de 60 ans à risc de forms sevère que nu l’auraient pas reçue dans les délais conseilles. It recalls the effectiveness of current (monovalent) vaccines against the severe forms of Covid-19.

À VOIR AUSSI – Covid-19: Moderna files a complaint against Pfizer and BioNTech for vaccine patent infringement

.

Leave a Comment